KalVista Appoints Brian Piekos as Chief Financial Officer
KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Brian Piekos as its new Chief Financial Officer. Piekos brings over 25 years of financial and strategic planning experience in the biopharmaceutical industry. He joins KalVista from Elicio Therapeutics, where he served as CFO. The appointment comes as KalVista prepares for the commercialization of sebetralstat, a potential novel therapy for hereditary angioedema.
As part of his employment agreement, Piekos received inducement options to purchase 100,000 shares of KalVista's Common Stock at an exercise price of $11.87 per share. These options will vest over a four-year period, subject to his continued service.
KalVista Pharmaceuticals (NASDAQ: KALV) ha nominato Brian Piekos come suo nuovo Chief Financial Officer. Piekos porta con sé oltre 25 anni di esperienza nella pianificazione finanziaria e strategica nell'industria biofarmaceutica. Arriva a KalVista da Elicio Therapeutics, dove ha ricoperto il ruolo di CFO. Questa nomina arriva mentre KalVista si prepara per la commercializzazione di sebetralstat, una potenziale nuova terapia per l'angioedema ereditario.
Come parte del suo accordo di lavoro, Piekos ha ricevuto opzioni di incentivo per acquistare 100.000 azioni delle azioni ordinarie di KalVista a un prezzo di esercizio di $11,87 per azione. Queste opzioni si matureranno nel corso di un periodo di quattro anni, soggetto alla sua continuazione nel servizio.
KalVista Pharmaceuticals (NASDAQ: KALV) ha nombrado a Brian Piekos como su nuevo Chief Financial Officer. Piekos aporta más de 25 años de experiencia en planificación financiera y estratégica en la industria biofarmacéutica. Se une a KalVista desde Elicio Therapeutics, donde se desempeñó como CFO. Este nombramiento se produce mientras KalVista se prepara para la comercialización de sebetralstat, una potencial nueva terapia para el angioedema hereditario.
Como parte de su acuerdo laboral, Piekos recibió opciones de incentivo para comprar 100,000 acciones de las acciones comunes de KalVista a un precio de ejercicio de $11.87 por acción. Estas opciones se consolidarán durante un período de cuatro años, sujeto a su servicio continuo.
KalVista Pharmaceuticals (NASDAQ: KALV)는 Brian Piekos를 새로운 Chief Financial Officer로 임명했습니다. Piekos는 생명공학 산업에서 재무 및 전략 계획 분야에서 25년 이상의 경험을 지니고 있습니다. 그는 Elicio Therapeutics에서 CFO로 재직하다 KalVista에 합류하게 되었습니다. 이번 임명은 KalVista가 유전성 혈관 부종에 대한 잠재적 신약인 sebetralstat의 상용화를 준비하고 있는 가운데 이루어졌습니다.
그의 고용계약의 일환으로, Piekos는 KalVista의 보통주 100,000주를 구매할 수 있는 유인 옵션을 받았습니다. 이 옵션은 $11.87의 행사 가격으로 제공되며, 그의 지속적인 근무에 따라 4년 동안 발생합니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a nommé Brian Piekos comme son nouveau Chief Financial Officer. Piekos apporte plus de 25 ans d'expérience en planification financière et stratégique dans l'industrie biopharmaceutique. Il rejoint KalVista depuis Elicio Therapeutics, où il a occupé le poste de CFO. Cette nomination intervient alors que KalVista se prépare à la commercialisation de sebetralstat, une thérapie potentielle novatrice pour l'angioedème héréditaire.
Dans le cadre de son contrat de travail, Piekos a reçu des options d'incitation pour acheter 100 000 actions des actions ordinaires de KalVista à un prix d'exercice de 11,87 $ par action. Ces options seront acquises sur une période de quatre ans, sous réserve de son service continu.
KalVista Pharmaceuticals (NASDAQ: KALV) hat Brian Piekos zu seinem neuen Chief Financial Officer ernannt. Piekos bringt über 25 Jahre Erfahrung in der finanziellen und strategischen Planung in der biopharmazeutischen Industrie mit. Er kommt von Elicio Therapeutics, wo er als CFO tätig war, zu KalVista. Diese Ernennung erfolgt, während KalVista sich auf die Kommerzialisierung von sebetralstat, einer potenziellen neuen Therapie für hereditäres Angioödem, vorbereitet.
Im Rahmen seines Arbeitsvertrags erhielt Piekos Anreizoptionen zum Kauf von 100.000 Aktien der Stammaktien von KalVista zu einem Ausübungspreis von 11,87 $ pro Aktie. Diese Optionen werden über einen Zeitraum von vier Jahren fällig, vorbehaltlich seiner fortgesetzten Dienstzeit.
- Appointment of an experienced CFO with 25+ years in the biopharmaceutical industry
- Preparation for commercialization of sebetralstat, a potential new treatment for hereditary angioedema
- Granting of inducement options to the new CFO, aligning his interests with the company's success
- None.
“Brian’s deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat,” said Ben Palleiko, Chief Executive Officer at KalVista. “I’m excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence.”
“I am excited to join KalVista at such an important time for the Company. The combination of a thoughtful, seasoned team, the breadth of positive data generated for sebetralstat, and the regulatory reviews underway, puts the Company in prime position to become a successful commercial organization,” said Mr. Piekos. “I look forward to embarking on this journey of bringing forward a novel therapy that has the potential to transform the treatment of hereditary angioedema.”
Brian Piekos has more than 25 years of financial and strategic planning experience in the biopharmaceutical industry. He joins KalVista from Elicio Therapeutics where he served as CFO and was responsible for launching Elicio as a public company. Previously, he served as CFO for Gemini Therapeutics and as Executive Vice President, CFO and Treasurer at AMAG Pharmaceuticals. Mr. Piekos held leadership roles in corporate finance, tax and treasury at Cubist Pharmaceuticals and began his career as a healthcare investment banker at Needham & Company and Leerink Partners.
Mr. Piekos earned his B.A. in biochemistry from Ithaca College, an M.S. in molecular biology from the University of Massachusetts Medical School, and his MBA from the Simon Business School at the University of
On September 9, 2024 Mr. Piekos was granted inducement options to purchase 100,000 shares of the Company’s Common Stock as inducement to Mr. Piekos’ entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025. In addition, KalVista received validation of its MAA from the EMA in August 2024. KalVista expects to file for approval in the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910275671/en/
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
Who is the new CFO of KalVista Pharmaceuticals (KALV)?
What is KalVista Pharmaceuticals (KALV) preparing to commercialize?
What stock options were granted to Brian Piekos upon joining KalVista (KALV)?